

Accepted Manuscript

Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population

Jake R. Morgan, Bruce R. Schackman, Jared A. Leff, Benjamin P. Linas, Alexander Y. Walley



PII: S0740-5472(16)30413-5
DOI: doi: [10.1016/j.jsat.2017.07.001](https://doi.org/10.1016/j.jsat.2017.07.001)
Reference: SAT 7608

To appear in:

Received date: 15 October 2016
Revised date: 30 May 2017
Accepted date: 1 July 2017

Please cite this article as: Jake R. Morgan, Bruce R. Schackman, Jared A. Leff, Benjamin P. Linas, Alexander Y. Walley , Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population, (2017), doi: [10.1016/j.jsat.2017.07.001](https://doi.org/10.1016/j.jsat.2017.07.001)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation
among individuals treated for opioid use disorder in a United States commercially insured
population**

MORGAN Jake R., PhD¹

SCHACKMAN Bruce R., PhD²

LEFF Jared A., MS²

LINAS Benjamin P., MD, MPH^{1, 3}

WALLEY Alexander Y., MD, MSc⁴

Department of Medicine, Section of Infectious Diseases, Boston Medical Center,¹ Boston, MA, USA; Department of Healthcare Policy & Research, Weill Cornell Medical College,² New York, NY, USA; Department of Epidemiology, Boston University School of Public Health,³ Boston, MA, USA; Department of Medicine, Section of General Internal Medicine, Boston Medical Center,⁴ Boston, MA, USA

WORD COUNT: 3,735 / ABSTRACT WORD COUNT: 474

This study was sponsored by the National Institute on Drug Abuse (P30DA040500 and R01DA031059), and benefited from copy-editing from Casy Calver (R25DA013582). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies or the US government.

Download English Version:

<https://daneshyari.com/en/article/6801913>

Download Persian Version:

<https://daneshyari.com/article/6801913>

[Daneshyari.com](https://daneshyari.com)